Evidence map›Paper›PMID 23426209›Full record

ArticleAnesthesiology2013

Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation.

Tony L Yaksh, Jeffery W Allen, Samantha L Veesart, Kjersti A Horais, Shelle A Malkmus, Miriam Scadeng, Joanne J Steinauer, Steve S Rossi

Open access · bronzeAbstract read
In one paragraph

Article in Anesthesiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. A perspective: neuraxial therapeutics in pain management: now and future.Frontiers in pain research (Lausanne, Switzerland) · 2024
    Article
  3. UltramicronizedBiomolecules · 2023
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Characterization of Analgesic Actions of the Chronic Intrathecal Infusion of H-Dmt-D-Arg-Phe-Lys-NH2 in Rat.Neuromodulation : journal of the International Neuromodulation Society · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tony L YakshAnesthesiology Research, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0818, USA. tyaksh@ucsd.edu
Jeffery W Allen
Samantha L Veesart
Kjersti A Horais
Shelle A Malkmus
Miriam Scadeng
Joanne J Steinauer
Steve S Rossi
Marymount University · USUniversity of California, San Diego · US

Funding

Characterization of Toxicity with Spinal OpiatesR01DA015353 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YAKSH, TONY L. · 2003 to 2017
$4.4M
NIDA NIH HHS R01 DA015353PHS HHS NIDA-15353
6 · The paper itself

Abstract

backgroundIntrathecal morphine forms granulomas that arise from the adjacent arachnoid membrane. The authors propose that these inflammatory cells exit the meningeal vasculature secondary to meningeal mast cell degranulation.

methodsThree sets of experiments were accomplished in dogs: (1) ex vivo meningeal mast cell degranulation (histamine release was measured ex vivo from canine dura incubated with opiates); (2) in vivo cutaneous mast cell degranulation (flare areas on the dog abdomen were measured after subcutaneous opiates); and (3) in vivo granuloma pharmacology. Dogs with lumbar intrathecal catheters received infusion of intrathecal saline or intrathecal morphine. Intrathecal morphine dogs received (1) no other treatment (control); (2) twice-daily subcutaneous naltrexone; (3) intrathecal co-infusion of cromolyn; or (4) twice-daily subcutaneous cromolyn for the 24- to 28-day study course.

resultsMorphine but not fentanyl evoked dural histamine release, which was blocked by cromolyn but not naloxone. Wheal/flare was produced by subcutaneous morphine, methadone, hydromorphone, but not fentanyl, and was unaffected by naltrexone but prevented by cromolyn. Granulomas occurred in all dogs receiving intrathecal morphine (15 of 15); subcutaneous naltrexone had no effect on granulomas (six of six) but was reduced by concurrent intrathecal cromolyn (zero of five) or twice-daily subcutaneous cromolyn (one of five).

conclusionsThe pharmacology of cutaneous/dural mast cell degranulation and intrathecal granulomas are comparable, not mediated by opioid receptors, and reduced by agents preventing mast cell degranulation. If an agent produces cutaneous mast cell degranulation at concentrations produced by intrathecal delivery, the agent may initiate granulomas.

Indexed as

Administration, CutaneousAnimalsDogsFemaleGranulomaHistamine ReleaseInjections, SpinalMaleMast CellsMeningesMorphineMorphine

Identifiers

PMID23426209
PMCPMC3788115
OpenAlexW2005876752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.